PDE4A and autoimmune polyendocrinopathy: The fact that increasing neutrophil cAMP and activating PKA would be beneficial for disease activity in mice aligns well with our previous work demonstrating the potential therapeutic target of this pathway in APS and lupus models with synthetic PDE4 inhibitors (22).